# Kura Oncology (KURA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/KURA
## Company Profile
- Ticker: KURA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 9.94 USD
- Market cap: 796306054.0500001 USD
- Last updated: 2026-08-12
## Business Overview
### Precision Oncology Company
Kura Oncology develops and commercializes small-molecule therapies for genetically defined cancers. Its portfolio focuses on menin inhibition in hematologic malignancies and farnesyl-transferase inhibition in solid tumors.
### KOMZIFTI
KOMZIFTI, or ziftomenib, is an FDA-approved oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Kura is expanding the drug into earlier treatment settings and genetically defined combination regimens.
### Menin Combination Programs
The KOMET clinical program evaluates ziftomenib with venetoclax and azacitidine, intensive chemotherapy, and FLT3 inhibitors. These studies seek to establish ziftomenib as a therapeutic backbone across the AML treatment continuum.
### Darlifarnib
Darlifarnib is a farnesyl-transferase inhibitor being developed as a precision combination agent in solid tumors. Current programs combine it with cabozantinib in renal-cell carcinoma and targeted RAS therapies in KRAS-mutated cancers.
### Emerging Menin Pipeline
Kura is also advancing next-generation menin inhibitors, including KO-7246 for diabetes and cardiometabolic disease, extending its menin expertise beyond oncology.
## Why The Stock Is Moving

The latest monitored company update is “Kura Oncology Reports Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Updated KOMET-007 data for ziftomenib plus venetoclax and azacitidine in newly diagnosed AML in the second half of 2026.
- Initial KOMET-007 data for ziftomenib with intensive chemotherapy and quizartinib in the second half of 2026.
- Initial KOMET-008 data for ziftomenib plus gilteritinib in relapsed or refractory AML in the second half of 2026.
- Completion of enrollment in the randomized Phase 1b FIT-001 study of darlifarnib plus cabozantinib in the first half of 2027.
- Initiation of a darlifarnib and daraxonrasib platform study in second-line or later pancreatic cancer in the first half of 2027.
- Initial clinical data from the randomized FIT-001 expansion in the second half of 2027.

## Drug Assets

- ziftomenib

## Recent News
- 2026-08-12 20:02 EST — [Kura Oncology Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/KURA/kura-oncology-reports-second-quarter-2026-financial-results-61b22816) — Source: Kura Oncology
- 2026-08-10 12:32 EST — [Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity](https://biopharmsignal.com/news/KURA/kura-oncology-announces-publication-in-blood-highlighting-ziftomenib-s-different-6c246da8) — Source: Kura Oncology
- 2026-08-07 11:30 EST — [Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-31057b4b) — Source: Kura Oncology
- 2026-08-05 11:30 EST — [Kura Oncology to Report Second Quarter Financial Results](https://biopharmsignal.com/news/KURA/kura-oncology-to-report-second-quarter-financial-results-074e0252) — Source: Kura Oncology
- 2026-07-27 10:32 EST — [Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026](https://biopharmsignal.com/news/KURA/kura-oncology-reports-durable-clinical-activity-of-darlifarnib-plus-cabozantinib-3697cd98) — Source: Kura Oncology